. 2019 Feb; 218(3):740-741.
doi: 10.1083/jcb.201810035.

Immune checkpoint inhibitors

Enfu Hui 1 
  • PMID: 30760493
  •     11 References
  •     16 citations

No abstract available

Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.
Giorgia Rota, Charlène Niogret, +8 authors, Greta Guarda.
Cell Rep, 2018 Apr 05; 23(1). PMID: 29617671
Highly Cited.
A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.
Tie Zheng Hou, Omar S Qureshi, +4 authors, David M Sansom.
J Immunol, 2015 Jan 30; 194(5). PMID: 25632005    Free PMC article.
The T-cell-receptor signaling network.
Morgan Huse.
J Cell Sci, 2009 Apr 24; 122(Pt 9). PMID: 19386893
Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.
Kok-Fai Kong, Guo Fu, +10 authors, Amnon Altman.
Nat Immunol, 2014 Apr 08; 15(5). PMID: 24705298    Free PMC article.
Highly Cited.
The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.
Michel DuPage, Gaurav Chopra, +7 authors, Jeffrey A Bluestone.
Immunity, 2015 Feb 15; 42(2). PMID: 25680271    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Confusing signals: recent progress in CTLA-4 biology.
Lucy S K Walker, David M Sansom.
Trends Immunol, 2015 Jan 15; 36(2). PMID: 25582039    Free PMC article.
Highly Cited. Review.
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.
Maria Gato-Cañas, Miren Zuazo, +14 authors, David Escors.
Cell Rep, 2017 Aug 24; 20(8). PMID: 28834746
Highly Cited.
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
Michael R Cassidy, Rachel E Wolchok, +5 authors, Charlotte Ariyan.
EBioMedicine, 2017 Mar 31; 18. PMID: 28356222    Free PMC article.
Molecular mechanisms of T cell co-stimulation and co-inhibition.
Lieping Chen, Dallas B Flies.
Nat Rev Immunol, 2013 Mar 09; 13(4). PMID: 23470321    Free PMC article.
Highly Cited. Review.
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling.
Kim Bich Nguyen, Stefani Spranger.
J Cell Biol, 2019 Dec 10; 219(1). PMID: 31816057    Free PMC article.
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Massimo Ralli, Andrea Botticelli, +6 authors, Antonio Greco.
J Immunol Res, 2020 Jul 17; 2020. PMID: 32671117    Free PMC article.
Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma.
Dafeng Xu, Yu Wang, +8 authors, Jinfang Zheng.
Onco Targets Ther, 2020 Sep 05; 13. PMID: 32884295    Free PMC article.
Differential CD4 T Regulatory Cell Phenotype Induced by Andes Hantavirus Glycoprotein.
Farides Saavedra, Jose L Garrido, +8 authors, Maria Ines Barria.
Front Cell Infect Microbiol, 2020 Sep 29; 10. PMID: 32984065    Free PMC article.
Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators.
Tilahun Ayane Debele, Cheng-Fa Yeh, Wen-Pin Su.
Cancers (Basel), 2020 Dec 19; 12(12). PMID: 33333816    Free PMC article.
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Congxin Dai, Siyu Liang, Bowen Sun, Jun Kang.
Front Endocrinol (Lausanne), 2020 Dec 29; 11. PMID: 33362722    Free PMC article.
Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
Marsha Pellegrino, Francesca Del Bufalo, +3 authors, Emmanuel de Billy.
Cells, 2020 Dec 31; 10(1). PMID: 33374128    Free PMC article.
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Tae Nakano-Tateno, Kheng Joe Lau, +4 authors, Takako Araki.
Front Endocrinol (Lausanne), 2021 Apr 13; 12. PMID: 33841328    Free PMC article.
From antibodies to living drugs: Quo vadis cancer immunotherapy?
Árpád Szöőr, János Szöllősi, György Vereb.
Biol Futur, 2021 Sep 24; 72(1). PMID: 34554498
The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma.
Noe Rico Montanari, Chimaobi M Anugwom, Andre Boonstra, Jose D Debes.
Cancers (Basel), 2021 Oct 14; 13(19). PMID: 34638361    Free PMC article.
Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.
Siddhartha Sood, Rahul Jayachandiran, Siyaram Pandey.
Integr Cancer Ther, 2021 Mar 16; 20. PMID: 33719631    Free PMC article.
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.
Maria Lucia Iacovino, Chiara Carmen Miceli, +9 authors, Felice Crocetto.
Int J Mol Sci, 2022 Feb 16; 23(3). PMID: 35163064    Free PMC article.
Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.
Carson R Reynolds, Son Tran, Mohit Jain, Aru Narendran.
Vaccines (Basel), 2022 Feb 27; 10(2). PMID: 35214655    Free PMC article.
AllergoOncology: Role of immune cells and immune proteins.
Mario Di Gioacchino, Loredana Della Valle, +2 authors, Sebastiano Gangemi.
Clin Transl Allergy, 2022 Mar 29; 12(3). PMID: 35344301    Free PMC article.
Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab.
Helen Hwang, Jiayi Huang, +7 authors, Jian L Campian.
CNS Oncol, 2022 Jan 20; 11(1). PMID: 35043686    Free PMC article.
Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.
Salmaan Kanji, Sydney Morin, +6 authors, Brian Hutton.
Drugs, 2022 Apr 14; 82(7). PMID: 35416592